SG10202007972SA - Biomarkers for response to ezh2 inhibitors - Google Patents

Biomarkers for response to ezh2 inhibitors

Info

Publication number
SG10202007972SA
SG10202007972SA SG10202007972SA SG10202007972SA SG10202007972SA SG 10202007972S A SG10202007972S A SG 10202007972SA SG 10202007972S A SG10202007972S A SG 10202007972SA SG 10202007972S A SG10202007972S A SG 10202007972SA SG 10202007972S A SG10202007972S A SG 10202007972SA
Authority
SG
Singapore
Prior art keywords
biomarkers
response
ezh2 inhibitors
ezh2
inhibitors
Prior art date
Application number
SG10202007972SA
Inventor
Ross Levine
Lindsay Lafave
Omar Abdel-Wahab
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of SG10202007972SA publication Critical patent/SG10202007972SA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91005Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011Methyltransferases (general) (2.1.1.)
    • G01N2333/91017Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer
SG10202007972SA 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors SG10202007972SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462014594P 2014-06-19 2014-06-19

Publications (1)

Publication Number Publication Date
SG10202007972SA true SG10202007972SA (en) 2020-10-29

Family

ID=54936135

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201610610YA SG11201610610YA (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors
SG10202007972SA SG10202007972SA (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201610610YA SG11201610610YA (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Country Status (15)

Country Link
US (1) US20170138946A1 (en)
EP (1) EP3158086B1 (en)
JP (1) JP6684230B2 (en)
KR (1) KR20170020463A (en)
CN (1) CN106795561B (en)
AU (1) AU2015276899B2 (en)
BR (1) BR112016029911A2 (en)
CA (1) CA2952285A1 (en)
EA (1) EA036889B1 (en)
ES (1) ES2870096T3 (en)
IL (1) IL249443B (en)
MX (1) MX2016017097A (en)
SG (2) SG11201610610YA (en)
WO (1) WO2015196064A1 (en)
ZA (1) ZA201608555B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108025191A (en) 2015-08-24 2018-05-11 Epizyme股份有限公司 The method for the treatment of cancer
TW201718598A (en) 2015-08-27 2017-06-01 美國禮來大藥廠 Inhibitors of EZH2
JP7336193B2 (en) * 2016-02-16 2023-08-31 エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ Epigenome profiling revealing somatic promoter properties in primary gastric adenocarcinoma
GB201615842D0 (en) * 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
CN106963765B (en) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Application of EZH2 inhibitor compound in preparation of medicine for treating ocular melanoma
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
EP0834576B1 (en) 1990-12-06 2002-01-16 Affymetrix, Inc. (a Delaware Corporation) Detection of nucleic acid sequences
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2001055454A1 (en) 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
KR20030031911A (en) 2001-04-19 2003-04-23 싸이퍼젠 바이오시스템즈, 인코포레이티드 Biomolecule characterization using mass spectrometry and affinity tags
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
IL160324A0 (en) 2001-08-13 2004-07-25 Beyond Genomics Inc Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
US20030199001A1 (en) 2002-04-23 2003-10-23 Pitt Aldo M. Sample preparation of biological fluids for proteomic applications
EP2500439B2 (en) 2005-06-20 2017-08-16 Advanced Cell Diagnostics, Inc. kits and products for detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations.
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
KR102061353B1 (en) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 Inhibitors of human ezh2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2676134A4 (en) * 2011-02-16 2015-04-08 Sloan Kettering Inst Cancer Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
AU2012315566A1 (en) * 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
KR102453519B1 (en) 2012-03-12 2022-10-11 에피자임, 인코포레이티드 Inhibitors of human ezh2, and methods of use thereof
LT2908823T (en) 2012-10-15 2019-10-25 Epizyme Inc Methods of treating cancer

Also Published As

Publication number Publication date
CN106795561B (en) 2021-04-16
KR20170020463A (en) 2017-02-22
IL249443B (en) 2022-05-01
SG11201610610YA (en) 2017-01-27
JP2017525337A (en) 2017-09-07
WO2015196064A1 (en) 2015-12-23
BR112016029911A2 (en) 2017-10-24
JP6684230B2 (en) 2020-04-22
AU2015276899B2 (en) 2021-08-12
ES2870096T3 (en) 2021-10-26
MX2016017097A (en) 2017-05-01
EP3158086B1 (en) 2021-03-24
CN106795561A (en) 2017-05-31
EA201692497A1 (en) 2017-06-30
EA036889B1 (en) 2021-01-12
EP3158086A1 (en) 2017-04-26
ZA201608555B (en) 2022-05-25
US20170138946A1 (en) 2017-05-18
AU2015276899A1 (en) 2017-01-05
CA2952285A1 (en) 2015-12-23
EP3158086A4 (en) 2018-01-10
IL249443A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
IL287113A (en) Smyd inhibitors
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL246902A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
GB201421083D0 (en) Enzyme inhibitors
GB201421088D0 (en) New enzyme inhibitors
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
EP3140427A4 (en) Biomarkers for response to pi3k inhibitors
IL257061A (en) Inhibitors of ezh2
GB201421085D0 (en) New enzyme inhibitors
GB2540917B (en) Solid acid scale inhibitors
ZA201608555B (en) Biomarkers for response to ezh2 inhibitors
GB201418154D0 (en) Inhibitors